<DOC>
	<DOCNO>NCT00244842</DOCNO>
	<brief_summary>The purpose study determine dose voclosporin effective treatment plaque psoriasis compare placebo .</brief_summary>
	<brief_title>Randomized Placebo-Controlled Study ISA247 Plaque Psoriasis</brief_title>
	<detailed_description>Psoriasis chronic skin condition significant impact patient 's physical mental well . The common form psoriasis plaque psoriasis . Targeted treatment psoriasis report recently , yet cyclosporine , calcineurin inhibitor ( CNi ) remain one treatment great efficacy . Voclosporin represent possibility calcineurin inhibitor efficacious cyclosporine A , also improve toxicity profile . Comparison ( ) : Voclosporin 3 dose level ( 0.2 , 0.3 , 0.4 mg/kg twice day ) compare placebo .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Plaque psoriasis ≥ 6 month prior screen . Diagnosis stable , plaque psoriasis ; i.e . psoriasis must spontaneously improve worsen 4 week prior screen visit . Plaque psoriasis involve ≥10 % body surface area ( BSA ) screen prior randomization day 0 visit . PASI score ≥10 screen prior randomization day 0 visit . Not pregnant nursing planning become pregnant course study . Sexually active woman childbearing potential less 1 year postmenopausal sexually active men surgically sterile must use reliable form birth control study treatment least 3 month last dose study drug . Surgically sterile female consider childbearing potential . Reliable form birth control include oral depot contraceptive , doublebarrier method . Written inform consent prior washout screen procedure . Able keep study appointment cooperate study requirement , opinion investigator . Has generalize erythrodermic , guttate , pustular psoriasis . Have dermatosis would interfere evaluation psoriasis , discretion investigator . A current malignancy history malignancy within 5 year history lymphoma time . Subjects enrol history squamous basal cell carcinoma surgically excise remove curettage electrodesiccation . Has current , uncontrolled bacterial , viral , fungal infection require intravenous antibiotic antifungal infection within 60 day prior screen . A history streptococcal infection require oral antibiotic within 30 day prior screen . A known history tuberculosis . Serologic evidence know latent human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) hepatitis C ( HCV ) virus . Uncontrolled hypertension define systolic blood pressure ≥150 mm Hg diastolic blood pressure ≥ 90 mm Hg . MDRD GFR ≤ 60 ml/min . Variation screen Visit 1 GFR ≥30 % . Alanine transaminase , aspartate transaminase , gammaglutamyl transferase ≥ 3x upper limit normal ( ULN ) . White blood cell count ≤ 2.8 x 109/L . Triglycerides ≥ 3x ULN . Requires follow prohibited medication treatment washout treatment period : drug potentiate nephrotoxicity voclosporin NSAID 's ACE inhibitor , drug interfere pharmacokinetics ; drug consider contribute psoriasis flare ; , systemic topical psoriasis medication ( include psoralen/ultraviolet A light treatment ) may interfere assessment study drug efficacy . Has use investigational drug device within 28 day 5 half life ( whichever longer ) prior screen visit . Has take biological agent ( ) , except flu shot , tetanus shot , booster , within 3 month start treatment . Biological agent include virus , therapeutic serum , toxin , antitoxin , analogous product applicable prevention , treatment , cure disease injuries man . Previous exposure voclosporin . A history clinically define allergy cyclosporine constituent voclosporin formulation ( vitamin E , medium chain triglyceride oil , Tween 40 , ethanol ) . A history alcoholism drug addiction within 1 year prior study entry . Weighs &lt; 45 kg ( 99 lb ) &gt; 140 kg ( 308 lb ) . A history disease , include mental/emotional disorder would interfere subject 's participation study , might cause administration ISA247 pose significant risk subject , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Chronic Disease</keyword>
	<keyword>Dermatologic Agents</keyword>
	<keyword>Female</keyword>
	<keyword>Humans</keyword>
	<keyword>Male</keyword>
	<keyword>Middle Aged</keyword>
	<keyword>Severity Illness Index</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Double-Blind Method</keyword>
</DOC>